204 related articles for article (PubMed ID: 33377175)
1. Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test.
Li Y; Li J; Li J
Histol Histopathol; 2021 Mar; 36(3):339-346. PubMed ID: 33377175
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
4. [Role of the pathologist in the processing of adenocarcinoma of the stomach, oesophagogastric junction and lower third of the oesophagus].
Svrcek M; Fléjou JF
Ann Pathol; 2011 Dec; 31(6):419-26. PubMed ID: 22172114
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.
Tanaka T; Fujimura A; Ichimura K; Yanai H; Sato Y; Takata K; Okada H; Kawano S; Tanabe S; Yoshino T
World J Gastroenterol; 2012 Nov; 18(43):6263-8. PubMed ID: 23180947
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
9. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
[TBL] [Abstract][Full Text] [Related]
10. Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma.
Huber AR; Buscaglia B; Koltz BR; Henry J; McMahon L; Guo J; Hicks DG; Whitney-Miller CL
Am J Clin Pathol; 2019 Apr; 151(5):461-468. PubMed ID: 30624589
[TBL] [Abstract][Full Text] [Related]
11. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types.
Fujimoto M; Matsuzaki I; Nishino M; Iwahashi Y; Warigaya K; Kojima F; Ono K; Murata SI
J Clin Pathol; 2018 Jul; 71(7):600-607. PubMed ID: 29305518
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
13. [Siewert-Stein classification of adenocarcinoma of the esophagogastric junction].
Szántó I; Vörös A; Gonda G; Nagy P; Altorjay A; Banai J; Gamal EM; Cserepes E
Magy Seb; 2001 Jun; 54(3):144-9. PubMed ID: 11432164
[TBL] [Abstract][Full Text] [Related]
14. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
15. Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma.
Blay C; Chiforeanu DC; Boucher E; Cabillic F; Desgrippes R; Leconte B; Perrin C; Manfredi S; Audrain O; Meunier B; Edeline J
Acta Oncol; 2015 Nov; 54(10):1833-5. PubMed ID: 25753188
[No Abstract] [Full Text] [Related]
16. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.
Aratani K; Komatsu S; Ichikawa D; Ohashi T; Miyamae M; Okajima W; Imamura T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Anticancer Res; 2017 Jun; 37(6):3129-3135. PubMed ID: 28551654
[TBL] [Abstract][Full Text] [Related]
18. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
19. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
Yoon HH; Sukov WR; Shi Q; Sattler CA; Wiktor AE; Diasio RB; Wu TT; Jenkins RB; Sinicrope FA
Cancer; 2014 Feb; 120(3):415-24. PubMed ID: 24151090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]